Olivier Capitain

2.0k total citations
59 papers, 826 citations indexed

About

Olivier Capitain is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Olivier Capitain has authored 59 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in Olivier Capitain's work include Cancer Treatment and Pharmacology (17 papers), Colorectal Cancer Treatments and Studies (16 papers) and Head and Neck Cancer Studies (12 papers). Olivier Capitain is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Colorectal Cancer Treatments and Studies (16 papers) and Head and Neck Cancer Studies (12 papers). Olivier Capitain collaborates with scholars based in France, United States and Spain. Olivier Capitain's co-authors include Alain Morel, Érick Gamelin, M. Boisdron‐Celle, Sophie Abadie‐Lacourtoisie, S Traoré, Gilles Simard, Agnès Dumont, Laurence Gamelin, B. Linot and Laurent Laccourreye and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Olivier Capitain

58 papers receiving 814 citations

Peers

Countries citing papers authored by Olivier Capitain

Since Specialization

Citations

This map shows the geographic impact of Olivier Capitain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Capitain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Capitain more than expected).

Fields of papers citing papers by Olivier Capitain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Capitain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Capitain. The network helps show where Olivier Capitain may publish in the future.

Co-authorship network of co-authors of Olivier Capitain

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Capitain. A scholar is included among the top collaborators of Olivier Capitain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Capitain. Olivier Capitain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma 2025 ·Journal of Clinical Oncology ·Michel Ducreux, (unknown), Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean‐Baptiste Bachet, (unknown), Thierry Lecomte, Olivier Capitain, Aurélie Parzy, (unknown), Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, (unknown), Valérie Lebrun-Ly, (unknown), Matthieu Texier, Olivier Bouché	3
2	Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer 2024 ·Digestive and Liver Disease ·(unknown), Morgane Caulet, Olivier Bouché, Christophe Borg, Sylvain Manfrédi, Olivier Capitain, Jean‐Philippe Spano, William Raoul, Maxime Guéguinou, Olivier Hérault, Aurélie Ferru, (unknown), Olivier Sire, Thierry Lecomte	1
3	Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers. 2023 ·Journal of Clinical Oncology ·Christophe Le Tourneau, Frédéric Rolland, Olivier Capitain, Amaury Daste, Philippe A. Cassier, Sébastien Salas, Luís Manso, Antonio Casado, Gerardo Colón‐Otero, Lauriane Eberst, (unknown), Ana I. Lalanne, Olivier Lantz, (unknown), Annette Tavernaro, Kaïdre Bendjama, (unknown), Jean‐Pierre Delord	0
4	Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients 2023 ·Clinical Pharmacokinetics ·(unknown), Gilles Paintaud, Nicolas Azzopardi, Christophe Passot, Morgane Caulet, (unknown), Céline Desvignes, Olivier Capitain, David Tougeron, Thierry Lecomte, David Ternant	1
5	Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients 2023 ·British Journal of Clinical Pharmacology ·(unknown), Morgane Caulet, Gilles Paintaud, Nicolas Azzopardi, Céline Desvignes, (unknown), Christophe Borg, Olivier Capitain, Aurélie Ferru, Olivier Bouché, Thierry Lecomte, David Ternant	1
6	Persistent elevation of plasma vitamin B12 is strongly associated with solid cancer 2021 ·Scientific Reports ·Valentin Lacombe, Floris Chabrun, Carole Lacout, A. Ghali, Olivier Capitain, Anne Patsouris, Christian Lavigne, G. Urbanski	31
7	Rehabilitation following total laryngectomy: Oncologic, functional, socio-occupational and psychological aspects 2020 ·European Annals of Otorhinolaryngology Head and Neck Diseases ·(unknown), R. Breheret, (unknown), Olivier Capitain, Laurent Laccourreye	13
8	63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies 2020 ·Annals of Oncology ·Christophe Le Tourneau, Philippe A. Cassier, Frédéric Rolland, Sébastien Salas, (unknown), Olivier Capitain, Olivier Lantz, Ana I. Lalanne, (unknown), Annette Tavernaro, (unknown), Kaïdre Bendjama, J.P. Delord	5
9	Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors 2018 ·European Journal of Cancer ·Béatrice Bouvard, (unknown), P Soulié, (unknown), Patrick Saulnier, Olivier Capitain, (unknown), Nathalie Mesgouez‐Nebout, É. Jadaud, Sophie Abadie‐Lacourtoisie, M. Campone, Érick Legrand	8
10	Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A comparative study 2018 ·European Journal of Surgical Oncology ·G. Lorimier, Valérie Seegers, (unknown), Denis Dupoiron, Emilie Thibaudeau, (unknown), (unknown), (unknown), Frédéric Dumont, Véronique Guerin‐Meyer, Olivier Capitain, Mario Campone, Romuald Wernert	5
11	The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit 2017 ·Annals of Oncology ·C. Mertens, H. Le Caer, Cécile Ortholan, Emmanuel Blot, Caroline Even, Hubert Rousselot, Frédéric Peyrade, Clément Sire, Didier Cupissol, Y. Pointreau, P. Debourdeau, Frédéric Rolland, Jérôme Fayette, Olivier Capitain, (unknown), (unknown), (unknown), Rabia Boulahssass, A. Aupérin, J. Guigay	10
12	Valeur pronostique du volume tumoral métabolique sur la TEP au (18F)-fluorodésoxyglucose préthérapeutique pour le cancer de l’œsophage localisé 2016 ·Cancer/Radiothérapie ·A. Paumier, (unknown), P. Trémolières, M. Lacombe, Olivier Capitain, Anne-Lise Septans, (unknown), (unknown), Aurélien Venara, (unknown), Dimitris Visvikis, Olivier Couturier, E. Rio, Mathieu Hatt	2
13	Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer 2016 ·European Journal of Surgical Oncology ·G. Lorimier, B. Linot, N. Paillocher, Denis Dupoiron, Véronique Verrièle, Romuald Wernert, A. Hamy, Olivier Capitain	30
14	Feasibility and safety of dose-dense modified docetaxel–cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study 2015 ·International Journal of Clinical Oncology ·(unknown), B. Linot, (unknown), R. Breheret, Laurent Laccourreye, Olivier Capitain	5
15	Sites de récidive après radiothérapie conformationnelle avec modulation d’intensité des carcinomes épidermoïdes des voies aérodigestives supérieures 2014 ·Cancer/Radiothérapie ·(unknown), (unknown), Y. Pointreau, Laurent Laccourreye, Olivier Capitain, (unknown), (unknown), (unknown), É. Jadaud, (unknown), P. Cellier, D. Autret, C. Tuchais	2
16	Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study 2014 ·Journal of Neuro-Oncology ·B. Linot, Mario Campone, Paule Augereau, R. Delva, Sophie Abadie‐Lacourtoisie, (unknown), Olivier Capitain	15
17	Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study 2012 ·Clinical Colorectal Cancer ·Olivier Capitain, (unknown), M. Boisdron‐Celle, (unknown), Alain Morel, Érick Gamelin	67
18	The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer 2007 ·The Pharmacogenomics Journal ·Olivier Capitain, M. Boisdron‐Celle, (unknown), Sophie Abadie‐Lacourtoisie, Alain Morel, Érick Gamelin	78
19	Pharmacogénétique des anticancéreux 2007 ·Annales Pharmaceutiques Françaises ·Érick Gamelin, M. Boisdron‐Celle, Alain Morel, Olivier Capitain	1
20	Hépatite cytolytique due à l’ésoméprazole au cours d’une chimiothérapie anticancéreuse 2005 ·La Presse Médicale ·Olivier Capitain, Alain Lortholary, Sophie Abadie‐Lacourtoisie	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact